BioPharma Credit
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of BioPharma Credit generated cash of $123,182,000, which is less than the previous year. Cash used in financing activities reached the amount of -$106,993,000 last year. Net change in cash is therefore $14,526,000.
Cash Flow
| 2017 | 23.06M | -354.74M | 632.33M |
|---|---|---|---|
| 2018 | 67.13M | -436.98M | 382.63M |
| 2019 | 131.52M | -100.29M | -98.14M |
| 2020 | 58.07M | -47.47M | -113.95M |
| 2021 | 96.43M | -94.82M | -100.15M |
| 2022 | 184.27M | 48.19M | -206.62M |
| 2023 | 123.18M | -1.65M | -106.99M |
BPCR.L Cash Flow Statement (2017 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
Cash at beginning of period | 120.52M | 94.70M | 193.26M | 296.63M | 363.57M | 350.82M | 0 |
Operating activities | |||||||
Net income | 108.45M | 182.31M | 84.95M | 89.13M | 122.32M | 70.14M | 27.16M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||
Depreciation and amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Stock-based compensation expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred income tax benefit | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Changes in operating assets and liabilities: | |||||||
Accounts receivable, net | -479K | -9.82M | -9.80M | 15.99M | 5.76M | -16.93M | -4.31M |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | -8.74M | 17.71M | 0 | 0 | 11.98M | 0 | 0 |
Cash generated by operating activities | 123.18M | 184.27M | 96.43M | 58.07M | 131.52M | 67.13M | 23.06M |
Investing activities | |||||||
Purchases Of Investments | -36.65M | -100M | -187.14M | -225.73M | -508.50M | -658.78M | 0 |
Investments In Property Plant And Equipment | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -1.65M | 48.19M | -94.82M | -47.47M | -100.29M | -436.98M | -354.74M |
Financing activities | |||||||
Common Stock Issued | 0 | 0 | 0 | 0 | 467K | 468.78M | 0 |
Payments for dividends | -89.77M | -156.53M | -100.15M | -113.89M | -98.61M | -74.04M | -6.53M |
Repurchases of common stock | -17.22M | -50.08M | 0 | -60K | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | -106.99M | -206.62M | -100.15M | -113.95M | -98.14M | 382.63M | 632.33M |
Net Change In Cash | 14.52M | 25.81M | -98.56M | -103.36M | -66.93M | 12.75M | 300.70M |
Cash at end of period | 135.05M | 120.52M | 94.70M | 193.26M | 296.63M | 363.57M | 300.70M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source |